1. Home
  2. BC vs ACAD Comparison

BC vs ACAD Comparison

Compare BC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brunswick Corporation

BC

Brunswick Corporation

HOLD

Current Price

$79.99

Market Cap

5.4B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.22

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BC
ACAD
Founded
1845
1993
Country
United States
United States
Employees
14000
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
4.4B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
BC
ACAD
Price
$79.99
$25.22
Analyst Decision
Buy
Buy
Analyst Count
11
22
Target Price
$83.55
$30.55
AVG Volume (30 Days)
587.9K
1.8M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
2.22%
N/A
EPS Growth
N/A
69.12
EPS
N/A
0.02
Revenue
N/A
$726,437,000.00
Revenue This Year
$9.81
$18.80
Revenue Next Year
$5.11
$11.70
P/E Ratio
N/A
$1,254.50
Revenue Growth
N/A
40.45
52 Week Low
$55.61
$19.69
52 Week High
$90.25
$28.35

Technical Indicators

Market Signals
Indicator
BC
ACAD
Relative Strength Index (RSI) 48.10 58.95
Support Level $78.23 $25.25
Resistance Level $85.00 $27.79
Average True Range (ATR) 2.80 0.77
MACD 0.01 -0.16
Stochastic Oscillator 47.73 29.52

Price Performance

Historical Comparison
BC
ACAD

About BC Brunswick Corporation

Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns more than 450 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: